文献速递淋巴瘤

磷酸肌醇-3与PIM激酶双重抑制剂IBL-202在模拟缺氧肿瘤微环境条件下对慢性淋巴细胞白血病细胞有效

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
PubMed 文献 · Br J Haematol · 2018-07-05

IBL-202是PIM和PI3激酶双重抑制剂。在模拟缺氧肿瘤微环境的体外条件下,IBL-202对慢性淋巴细胞白血病(CLL)细胞具有细胞毒性,而idelalisib没有;IBL-202还显著影响CLL细胞的CD49d和CXCR4表达、迁移、周期和增殖。数据表明IBL-202双重抑制PIM和PI3激酶可能是靶向CLL细胞的有效策略,尤其是在已知赋予耐药性的环境生态位中。

要点

  • 在模拟缺氧肿瘤微环境的体外条件下,IBL-202对CLL细胞有细胞毒性,idelalisib没有。
  • IBL-202显著影响CLL细胞的CD49d和CXCR4表达、迁移、周期和增殖。
  • IBL-202双重抑制PIM和PI3激酶可能是靶向CLL细胞的有效策略。

核心结论

  • IBL-202双重抑制PIM和PI3激酶可能是靶向CLL细胞的有效策略,尤其是在已知赋予耐药性的环境生态位中。

研究设计与样本

  • 临床前体外研究,使用多种血液系统细胞系和原代CLL细胞。

主要发现

  • 泛PIM抑制剂pPIMi与idelalisib对多种血液系统细胞系和原代CLL细胞具有协同作用,支持IBL-202在CLL中开展临床前研究的理由。
  • 在模拟缺氧肿瘤微环境的体外条件下,IBL-202对CLL细胞具有细胞毒性,而idelalisib没有。
  • IBL-202对CLL细胞的CD49d和CXCR4表达和迁移、周期和增殖有显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become important treatment options for the disease and demonstrate the potential of targeting components of the B-cell receptor-signalling pathway. IBL-202 is a dual inhibitor of the PIM and PI3 kinases. Synergy between the pan-PIM inhibitor, pPIMi, and idelalisib against a range of haematological cell lines and primary CLL cells supports the rationale for preclinical studies of IBL-202 in CLL. Importantly, IBL-202, but not idelalisib, was cytotoxic against CLL cells under in vitro conditions that mimic the hypoxic tumour microenvironment. The significant effects of IBL-202 on CD49d and CXCR4 expression and migration, cycle and proliferation of CLL cells suggest the drug may also interfere with the migratory and proliferative capacity of the leukaemic cells. Collectively, these data demonstrate that dual inhibition of the PIM and PI3 kinases by IBL-202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug-resistance.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Crassini K, Shen Y, O'Dwyer M, et al. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Br J Haematol. 2018. PMID: 29978459. doi:10.1111/bjh.15447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。